A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma

NCT02596321 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergy
Asthma
Rhinitis

Interventions

DRUG: Mitizax
DRUG: Placebo

Sponsor

Abbott

Collaborators

[object Object]
[object Object]